tbuckley/cabot-search huggingface dataset:
RELATIONSHIP OF T1-201 SCINTIGRAPHY TO I-131 SCANS AND THYROGLOBULIN (Tg) ASSAYS IN FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA (DTC) PTS.
Authors: Lalitha Ramanna, Alan Waxman, Michael Brachman, Doina Tanasescu, Glenn Braunstein
Journal: Clinical Nuclear Medicine (1987)

Ramanna, Lalitha; Waxman, Alan; Brachman, Michael; Tanasescu, Doina; Braunstein, GlennAuthor Information
AB0522 Clinical Characteristics of Muscular Symptoms in Patients with Systemic Lupus Erythematosus
Authors: K. Noda, M. Yoshiga, K. Otani, H. Ito, K. Hirai, K. Furuya, T. Ukichi, K. Yoshida, I. Kingetsu, D. Kurosaka
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> It is well known that myalgia occurs in 40% to 80% of patients with systemic lupus erythematosus (SLE). However, the clinical charasteristics of muscular symptoms associated SLE has not been studied enough. <h3>Objectives</h3> The aim of this study is to analyze the clinical characteristics of muscular symptoms associated SLE. <h3>Methods</h3> We retrospectively reviewed the medical record of SLE patient who presented muscular symptoms (muscle weakness or myalgia) between January 2010 and December 2012. We identified 7 SLE patients who developed muscular symptoms. The clinical characteristics, muscle enzymes, laboratory data, MRI fingings, and pathological findings were analyzed. <h3>Results</h3> At the time of muscle symptom onset, the mean patient age was 32.7±11.1 years, with a male-female ratio of 1:6. All cases showed low complement levels, and showed elevated levels of ds-DNA antibodies. The mean SLE Disease Activity Index (SLEDAI) was 16±6.22. Serum creatine kinase was elevated in 1 of the 7 cases. Meanwhile, all cases showed increased aldolase and the STIR MRI of the muscles revealed a high intensity signal showing myofascial dominance over muscle. Moreover, en bloc biopsy was performed in 4 cases and like the MRI findings, myofascial-dominant mononuclear cell infiltrates were observed. In all cases, a moderate to high dose of prednisolone was administered and muscle symptoms improved. This was accompanied by an improvement in muscle symptoms, decreases in aldolase, ds-DNA antibodies and SLEDAI, and an increase in complement levels. <h3>Conclusions</h3> In SLE patients with muscular symptoms, fasciitis was demonstrated by MRI or pathological findings. Fasciitis may contribute to muscular symptoms in patients with SLE. <h3>References</h3> Tsokos GC, Moutsopoulos HM, Steinberg AD. Muscle involvement in systemic lupus erythematosus. JAMA 1981;246:766-8. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1910
579 MYOCARDIAL INFARCT-SPARING EFFECT OF ISCHEMIC PRECONDITIONING ABROGATED IN CIRRHOTIC RAT THROUGH INVOLVEMENT OF MITOCHONDRIAL PERMEABILITY TRANSITION PORE
Authors: V. Khori, A.R. Dehpour, N. Mohsen, H.R. Mohimani, F. Jafrazedeh
Journal: Journal of Hepatology (2012)
1360 PREDICTIVE CRITERIA OF LATE MORTALITY OF 3RD (M3) TO 6TH MONTH (M6) FOLLOW-UP IN PATIENTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (AAH) TREATED WITH CORTICOSTEROIDS
Authors: G. Macaigne, P. Lahmek, F. Harnois, J.F. Boivin, A. Ferrario, S. Cheaib, D. Dikov, G. Bonihay, C. Chayette
Journal: Journal of Hepatology (2012)
1336 NON-ALCOHOLIC STEATOHEPATITIS INCREASES THE PRODUCTION OF ANTIBODIES AGAINST OXIDIZED LDL, ATHEROSCLEROSIS AND CARDIOVASCULAR RISK
Authors: R. Gallego-Durán, J. Ampuero, I. Ranchal, R. Aparcero, R. Picón, H. Pastor, F.J. Molano, F.L. Pastor, M. Romero-Gómez
Journal: Journal of Hepatology (2013)
P5-18-01: No Effect of Adjuvant Chemotherapy in Postmenopausal Patients with Invasive Lobular (Mixed) Breast Cancer.
Authors: W Truin, A Voogd, G Vreugdenhil, der Heiden-van der Loo M Van, S Siesling, R Roumen
Journal: Cancer Research (2011)

Abstract Background: Although the literature is clear concerning the lack of response of invasive lobular breast cancer to neoadjuvant chemotherapy, no studies exist on the effectiveness of the adjuvant use of chemotherapy in these patients, as compared to those with ductal and mixed type lobular cancer. Methods: All women with primary non-metastatic invasive ductal or (mixed type) lobular breast cancer, aged 50 to 69 years, diagnosed in the period 1995 to 2008 and treated with surgery, were selected from the Netherlands Cancer Registry and followed until January 1, 2010. Patients were divided in two groups: those who received adjuvant hormonal therapy only versus those receiving hormonal therapy in combination with adjuvant chemotherapy. Cox proportional hazards analyses were carried out to determine the impact of chemotherapy in addition to hormonal treatment, for each histological entity separately. Results: In total 19,609 patients had ductal cancer, 3,685 had pure lobular cancer and 1,391 had mixed type lobular cancer. The patient groups were comparable with respect to the use of adjuvant systemic treatment. The 10-year survival of patients with ductal cancer treated with hormonal therapy alone was 69%, compared to 74% for those treated with hormonal therapy and chemotherapy (P&amp;lt;.0001). For patients with lobular cancer, the 10-year survival rate was 68% after hormonal treatment alone and 66% after hormonal therapy with chemotherapy (P=.45). The hazard ratio for death among the patients with ductal cancer receiving chemotherapy in addition to hormonal treatment was 0.70 (95% CI, 0.64−0.76, p&amp;lt;0.0001), as compared to those receiving hormonal treatment alone. In patients with pure or mixed type lobular cancer, however, the hazard ratio's were 1.00 (95% CI, 0.82−1.21, p=0.97) and 0.98 (95% CI, 0.70−1.33, p=0.83), respectively. A statistically significant interaction was observed between the use of adjuvant chemotherapy and histological tumor type. Conclusions: Adjuvant chemotherapy confers no additional beneficial effects in postmenopausal patients with pure or mixed type lobular breast cancer receiving hormonal therapy. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-01.
Abstract 4355: Metformin potentiates the efficacy of radiotherapy of tumors by eliminating cancer stem cells
Authors: Bo-Hwa Choi, Hyemi Lee, Moon-Taek Park, Eun-Taex Oh, Min-Jeong Song, Chang Won Song, Heon Joo Park
Journal: Cancer Research (2011)

Abstract Metformin, a widely used drug for type II diabetes, possess significant anti-cancer property. In a recent study, metformin was able to selectively kill chemoresistant cancer stem cells (CSCs). It has been known that CSCs are resistant to irradiation and, thus, they are responsible for the recurrence of cancer after radiotherapy. The purpose of the present study was to investigate whether metformin enhances the response of tumors to radiotherapy by eradicating radioresistant CSCs. An incubation with metformin at 0.1 mM – 10 mM for 72 hours caused clonogenic cell death in a dose-dependent manner in MCF-7 human breast cancer cells, MIA PaCa-2 human pancreatic cancer cells, and FSaII mouse fibrosarcoma cells. In addition, the clonogenic cell death was enhanced by using the combination of metformin and irradiation. We then investigated the effect of metformin on CSCs of the three cell lines, which were identified by ALDH-1 activity, CD24low/CD44+ expression, and SP method. Metformin was preferentially cytotoxic to CSCs in all these cell lines. The formation of mammospheres from MCF-7 cells was also markedly inhibited by metformin. Both metformin and irradiation activated AMPK and suppressed the mTOR-S6K signaling pathway. Combined treatment of cells with metformin and irradiation was far more effective in activating AMPK and suppressing the mTOR-S6K pathway. The combined effects of metformin and X-irradiation on the growth of FSaII tumors induced in the hind legs of C3H mice were studied. Metformin treatment at 50 – 100 mg/kg/day, i.p., slightly suppressed the tumor growth, but it strikely potentiated the response of tumors to 20 Gy X-irradiation in a single exposure. It was likely that metformin treatment depleted the radioresistant CSCs in the tumors, thereby markedly enhancing the response of tumors to irradiation. However, in addition to killing CSCs, the possibility that metformin radiosensitized CSCs as well as non-CSCs could not be excluded. Our results demonstrated for the first time that metformin is potentially useful for enhancing the efficacy of radiotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4355. doi:10.1158/1538-7445.AM2011-4355
Variability in the application of contemporary diagnostic criteria: endogenous depression as an example
Authors: M Zimmerman, W H Coryell, D W Black
Journal: American Journal of Psychiatry (1990)

Specified diagnostic criteria have been credited, in part, with improving diagnostic reliability. The authors hypothesize that nonuniform application of these criteria across different research centers has been one factor responsible for the failure to replicate research findings. For example, researchers using a narrow interpretation of the Research Diagnostic Criteria (RDC) have found a highly significant association between endogenous depression and a positive dexamethasone suppression test result, whereas researchers using a broad interpretation have failed to find the predicted relationship. The authors used two interpretations of the RDC and DSM-III endogenous/melancholia criteria to diagnose 60 depressed patients and found significant difference in rates of diagnoses and symptoms.
Diagnostic Usefulness and Safety of Transtracheal Aspiration
Authors: Robert W. Kalinske, Richard H. Parker, David Brandt, Paul D. Hoeprich
Journal: New England Journal of Medicine (1967)

ACCURATE interpretation of the significance of the isolation of potentially pathogenic microorganisms by culture of expectorated respiratory-tract secretions is frequently impossible. Often, such material contains micro-organisms not recoverable by more direct means of culturing the lower respiratory tract.1 2 3 4 The problem cannot be solved by the usual transpharyngeal technics. Bronchoscopy is too specialized and too cumbersome for routine clinical use1 , 2 , 4; in selected patients, however, the possibility of acquiring additional useful information by direct visualization of the lower respiratory tract recommends bronchoscopy. Catheters, peroral and nasal, are invariably soiled with pharyngeal secretions in the course of the generally unsuccessful battle to . . .
Neu-Protein Overexpression in Breast Cancer
Authors: Marc J. van de Vijver, Johannes L. Peterse, Wolter J. Mooi, Peter Wisman, Job Lomans, Otilia Dalesio, Roel Nusse
Journal: New England Journal of Medicine (1988)

Amplification of the neu proto-oncogene in breast cancer has been reported to correlate with the presence of lymph-node metastases and with a poor prognosis. We describe a method for the immunohistochemical detection of overexpression of neu protein on formalin-fixed paraffin-embedded tissue, with the use of two different monoclonal antibodies. In a group of tumors with a known neu-gene copy number, intense membrane staining of tumor cells was present in all tumors with neu-gene amplification. Of 189 tumors from patients with Stage II breast cancer, 27 (14 percent) had neu-membrane staining. Neu overexpression was associated with larger tumor size (P = 0.006) but not with lymph-node involvement. Neu-protein expression in lymph-node metastases was the same as its expression in primary tumors. Among the patients with neu overexpression (median follow-up, 37 months), disease-free survival was not significantly shorter; overall survival was reduced significantly in these patients (P = 0.042), but this reduction did not remain significant after adjustment for tumor size. Of 45 ductal carcinomas in situ, 19 (42 percent) had neu-membrane staining. These 19 were all of the large-cell, comedo growth type. None of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type had neu overexpression. We conclude that neu overexpression may be an early step in the development of a distinct histologic type of carcinoma of the breast, but we could find no association of overexpression with lymph-node status or tumor recurrence. (N Engl J Med 1988; 319: 1239–45.)
Growing Hepatic Cavernous Hemangioma Demonstrated by Tc-99m Red Blood Cell Scintigraphy
Authors: MIGUEL GORENBERG, WLADIMIR SOPOV, DAVID GROSHAR
Journal: Clinical Nuclear Medicine (2000)

Hepatic cavernous hemangiomas rarely grow. Although a few cases have been reported in the literature, none used Tc-99m red blood cell scintigraphy. The authors describe such a case here.
P697Evaluation of tp-te interval and tp-te/qt ratio in patients with coronary slow flow tp-te/qt ratio and coronary slow flow: Table 1.
Authors: K Karaagac, M Demir, O C Yontar, E Tenekecioglu, F Vatansever, O Arican Ozluk, A Tutuncu, B Arslan, M Yilmaz
Journal: Cardiovascular Research (2014)

Aims: Coronary slow flow (CSF) phenomenon is described by angiographically normal coronary arteries with delayed opacification of the distal vasculature. Studies have suggested that the interval from the peak to the end of the electrocardiographic T wave (Tp-Te) may correspond to the transmural dispersion of repolarization and that increased Tp-Te interval and Tp-Te/QT ratio are associated with malignant ventricular arrhythmias. The aim of this study was to evaluate ventricular repolarization by using Tp-Te interval and Tp-Te/QT ratio in patients with CSF.
Abstract 1483: Bmi1 is required for Twist1-mediated breast cancer cell invasion.
Authors: Yu-Huey Lin, Guihua Jing, Junjun Liu
Journal: Cancer Research (2013)

Abstract Metastasis is the spread of cancer cells from the site of primary tumors to distant organs and the establishment of secondary tumors there. It is a multistep process, and the initial step is cancer cell invasion during which cancer cells move into tissues surrounding the tumor and the vasculature. Transcription factor Twist1 has been identified as a key regulator of metastasis in a murine breast tumor model as suppression of Twist1 expression in metastatic mammary carcinoma cells specifically inhibits their ability to metastasize, and overexpression of Twist1 induces cell motility and promotes an epithelial-mesenchymal transition (EMT). Previous studies have shown that Twist1 works together with polycomb group protein Bmi1 to promote EMT. Here we show that in breast cancer cells, Bmi1 acts downstream of Twist1 to promote the cancer cell invasion. Suppression of Bmi1 in breast cancer cells expressing high level Twist1 reduces cell motility, and ectopic expression of Bmi1 in Twist1-knockdown cells promote cell invasion. The results delineate a novel pathway that leads to cancer cell invasion and metastasis, which may benefit the development of novel therapeutic approaches to treat advanced breast cancer. Citation Format: Yu-Huey Lin, Guihua Jing, Junjun Liu. Bmi1 is required for Twist1-mediated breast cancer cell invasion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1483. doi:10.1158/1538-7445.AM2013-1483 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
THU0171 Influence of Immunogenicity of Anti-TNF Therapy in RA Patients with a Long-Term Treatment with Infliximab or Adalimumab
Authors: A. Villalba, C. Plasencia, D. Peiteado, L. Nuño, G. Bonilla, L. Lojo, D. Pascual, R. del Moral, M. T. López Casla, A. Balsa, E. Martin Mola
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The anti-TNF therapy has been a great progress in RA patients treatment. However, a proportion of patients develop primary inefficacy or loss of response, resulting in switching or treatment discontinuation. Recent studies correlate the antidrug antibodies (ADA) development with loss of efficacy. <h3>Objectives</h3> To asses in RA patients treated with infliximab (Ifx) or adalimumab (Ada) whether ADA development influences on the clinical efficacy and treatment duration. <h3>Methods</h3> We studied ambispectively 174 RA patients from La Paz University Hospital who received Ifx or Ada between years 2000-2012, both in combination with synthetic DMARDs or in monotherapy. The assessment of disease activity was performed by Disease Activity Score 28 (DAS28) and clinical improvement by delta-DAS28. Measurements were performed at baseline, 1, 2 and ≥ 3 years under the biological therapy (BT). ADA and drug levels were measured by ELISA. Statistical analysis was performed using SPSS 11.0. <h3>Results</h3> Of the 174 patients, 140 (80.5%) were women. The mean age was 57 ± 13.2 years and the disease duration was 14.7 ± 8.0 years. 128 patients (73.6%) were RF positive. The mean duration on BT was 5.0 ± 3.0 years. One hundred fifty patients (86.2%) received methotrexate, 98 other DMARDs (56.3%) and 11 (6.3%) were in monotherapy. The mean DAS28 at baseline was 5.28 ± 1.26 and there was no significant differences between DAS28 at baseline in patients with or without ADA ( 5,28±1,47 ADA+ vs 5,25±1,19 ADA-, p=0,918). Along the study, 62 patients (35.6%) developed ADA (47/105 patients (44.8%) to Ifx and 15/69 patients (21.7%) to Ada, p = 0.002). Ninety six (55.2%) patients dropped out the BT and this was more frequent in ADA positive patients [49/62 (79.0%) ADA+ vs. 47/112 (41.9%) ADA-, p &lt;0.00001]. Most patients who discontinued by inefficacy had ADA [25/39 (64.1%) ADA+ vs 14/39 (35.9%) ADA-, p = 0.039]. Patients with ADA were more active in all studied point (at 1<sup>st</sup> year: 4.69 ± 1.15 ADA+ vs 3.43 ± 1.22 ADA-, p&lt;0.0001; at 2<sup>nd</sup> year: 3.96 ± 1.40 ADA+ vs 3.08 ± 1.09 ADA-, p= 0.015; at 3<sup>rd</sup> year: 4.34 ± 1.26 ADA+ vs 3.21 ± 1.56 ADA-, p = 0.001). The clinical improvement was lower in ADA positive patients along this work (at 1<sup>st</sup> year: 0.94 ± 1.06 ADA+ vs 1.63 ± 1.32 ADA-, p = 0.045; at 2<sup>nd</sup> year: 0.72 ± 1,05 ADA+ vs. 1.83 ± 1.59 ADA-, p =0.021; at 3<sup>rd</sup> year: 0.44 ± 1.26 ADA+ vs 2,02 ± 1.87 ADA-, p&lt;0.0001). <h3>Conclusions</h3> The ADA development in RA patients treated with Ifx or Ada is correlated with a clinical inefficacy and with the therapy survival, resulting in an earlier therapy discontinuation. <h3>Disclosure of Interest</h3> None Declared
Talking with Patients about Other Clinicians' Errors
Authors: Thomas H. Gallagher, Michelle M. Mello, Wendy Levinson, Matthew K. Wynia, Ajit K. Sachdeva, Lois Snyder Sulmasy, Robert D. Truog, James Conway, Kathleen Mazor, Alan Lembitz, Sigall K. Bell, Lauge Sokol-Hessner, Jo Shapiro, Ann-Louise Puopolo, Robert Arnold
Journal: New England Journal of Medicine (2013)

The authors discuss the challenges facing a clinician who discovers that her patient has been harmed by another health care worker's medical error. They provide guidance to help clinicians and institutions disclose such errors to patients.
P17.91 * CLINICAL VARIABLES SERVE AS PREDICTIVE FACTORS IN A MODEL FOR CLINICAL RESPONSE TO BEVACIZUMAB IN RECURRENT GLIOBLASTOMA MULTIFORME: AN OBSERVATIONAL STUDY OF A COHORT OF CONSECUTIVE NON-SELECTED PATIENTS FROM A SINGLE INSTITUTION
Authors: T. Urup, K. Grunnet, I. J. Christensen, S. R. Michaelsen, H. Broholm, M. T. Stockhausen, U. Lassen, H. S. Poulsen
Journal: Neuro-Oncology (2014)

Bevacizumab (BEV), a humanized monoclonal antibody against vascular endothelial growth factor A, has demonstrated activity in patients with recurrent glioblastoma multiforme (GBM). Few previous small sample-size studies have correlated various factors to treatment response, although no predictive parameters have yet been determined. More studies and new approaches to identify the patients that clinically benefit from BEV are therefore in great demand. The primary end-point was to identify the predictive factors of BEV response in patients with recurrent GBM, this single center study retrospectively analyze 196 consecutive, non-selected recurrent primary and secondary GBM patients with ECOG performance status 0-2 who were treated with BEV combination therapy from May 2005 to December 2013. The secondary end-point point was to identify prognostic factors for overall survival (OS) and progression-free survival (PFS). Factors that were analyzed as potential markers of predictive significance included: Age, corticosteroid at start of therapy, increase in corticosteroid dose during the 2 first series, PS at start of therapy, PS after 2 series, PS at best response, gender, extent of resection, tumor location, tumor size, secondary GBM, prior line of chemotherapy, p53, EGFR and MGMT expression. Univariate and multivariate analysis of response data were performed using logistic regression analysis modeling the probability of MacDonald response at 2 months as well as the best response. Estimates of survival probabilities for OS and PFS were performed by Kaplan-Meier method. Univariate and multivariate analyses of OS and PFS for the chosen explanatory variables were performed using Cox regression model. P values <.05 were considered significant. Calculations have been performed using SPSS and SAS software. Results from analysis will be presented.
Distal esophageal involvement in Crohn disease: short treatment with adalimumab
Authors: D. Musto, L. Martorelli, A. Cirillo, F. Selvaggi, P. Esposito, M. Russo, G. Riegler
Journal: Endoscopy (2010)

The proximal gastrointestinal tract is involved in Crohn disease in less than 4 % of cases [1]. Esophageal involvement occurs in between 0.3 % and 2 % of the total patient population [2]. Upper gastrointestinal involvement is symptomatic or, more rarely, can be asymptomatic, as described by Souza et al. [3].